Skip to content
OpenCapital
Get started

Replimune Group REPL Quick ratio

Quick ratio at other companies

Amgen logo
AmgenAMGN
1×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3×-1.1×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.5×+1.3×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
CG Oncology logo
CG OncologyCGON
31.3×+0.3×
Erasca, Inc. logo
Erasca, Inc.ERAS
9.5×-2.8×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

quick assets/total current liabilities=5.6×

Based on the most recent quarter.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's quick ratio?
Replimune Group (REPL) reported quick ratio of 5.6× in Q4 2025.
How has Replimune Group's quick ratio changed year-over-year?
Replimune Group's quick ratio decreased by 51.0% year-over-year, from 11.4× to 5.6×.
What is the long-term trend for Replimune Group's quick ratio?
Over 4 years (2021 to 2025), Replimune Group's quick ratio has grown at a -30.1% compound annual growth rate (CAGR), from 33.3× to 8×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.